Consistent Revenue Growth
Zimmer Biomet reported nearly 5% constant currency sales growth for Q4 2024, marking the 12th consecutive quarter of mid-single-digit or better growth.
Strategic Acquisition of Paragon 28
Zimmer Biomet announced the acquisition of Paragon 28, a leader in the $5 billion foot and ankle space, expected to close in the first half of 2025, enhancing their lower extremity product offerings.
Positive Pricing Trends
Achieved positive pricing for the fourth consecutive quarter with 60 basis points improvement, signaling strong pricing power.
Operational Excellence Initiatives
Implemented new leadership in key areas and announced over 50 new product launches in the next 36 months, focusing on innovation and diversification.
Strong Performance in S.E.T. Segment
The S.E.T. segment grew 8.4% globally, outpacing growth in knees and hips, indicating a successful diversification strategy.